Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Enfermedad de Alzheimer y Demencias

634 ARTÍCULOS , VIENDO DEL 526 AL 540

Disease modifying treatments for Alzheimer's disease: Clinician perspectives

Pennington C, Apurva P, Chen A, Duncan A, Mackay G, Masters H, Paramore K, Russ T, Skinner H, Zeidler M.

J Alzheimers Dis. 2026 May;111(1):125-131. doi: 10.1177/13872877261429859. Epub 2026 Mar 25.

Nanomaterials for Alzheimer's disease: emerging strategies in diagnosis and therapy

Na Y, Bai J, Zhang N, Geng F, Wang X.

J Nanobiotechnology. 2026 Mar 21;24(1):398. doi: 10.1186/s12951-026-04281-w.

CSF proteomics of semorinemab Alzheimer's disease trials identifies cell-type specific signatures

Abdel-Haleem AM, Casavant E, Toth B, Teng E, Monteiro C, Pandya NJ, Glock C, Hoogenraad CC, Friedman BA, Yeh FL, Anania VG, Novikova G.

Brain. 2026 Jan 8;149(1):150-162. doi: 10.1093/brain/awaf200.

Serious doubts about amyloid-β (Aβ) biomarkers and anti-Aβ immunotherapy

Høilund-Carlsen PF, Alavi A, Costa T, Neve RL, Revheim ME, Barrio JR.

J Alzheimers Dis. 2026 Apr;110(3):1079-1084. doi: 10.1177/13872877261417548. Epub 2026 Mar 20.

The Basis of Anti-Aβ Antibody Therapy: The Toxicity of Aβ Aggregates and the Mechanism of Action of Anti-Aβ Antibodies

Ono K, Noguchi-Shinohara M, Watanabe-Nakayama T.

Intern Med. 2026 Jan 1;65(1):41-45. doi: 10.2169/internalmedicine.4569-24. Epub 2024 Oct 4.

Anti-amyloid β Antibody Therapies for Alzheimer's Disease: Association between the Target of Amyloid β Aggregates and the Clinical Efficacy of Anti-amyloid β Antibody

Noguchi-Shinohara M, Ono K.

Intern Med. 2026 Jan 1;65(1):67-70. doi: 10.2169/internalmedicine.4604-24. Epub 2024 Oct 11.

Experimental Models and Translational Strategies in Neuroprotective Drug Development with Emphasis on Alzheimer's Disease

Niziński P, Szalast K, Makuch-Kocka A, Paruch-Nosek K, Ciechanowska M, Plech T.

Molecules. 2026 Jan 16;31(2):320. doi: 10.3390/molecules31020320.

The role of Annexin A2 in Alzheimer's disease: From cellular functions to therapeutic potential

Shu D, Fu C, Liu Z, Li C.

FEBS J. 2026 May 6. doi: 10.1111/febs.70574. Online ahead of print.

Wernicke's encephalopathy unmasking progressive supranuclear palsy and Alzheimer's pathology: a diagnostic challenge in an older adult

Defalque I, Ribeiro Da Costa R, Scheffler M, Mendes A.

BMJ Case Rep. 2026 Jan 6;19(1):e269430. doi: 10.1136/bcr-2025-269430.

Phytoconstituents as Potential Therapeutics against Enzymatic Targets for Neurodegenerative Diseases

Singh H, Pandey VP.

Curr Protein Pept Sci. 2026;27(1):46-65. doi: 10.2174/0113892037350938250514110643.

Resveratrol and the neuroinflammation axis in Alzheimer's disease, Parkinson's disease, multiple sclerosis, and cerebral ischemia

Wang H, Li F, Wang H, Tian Z, Fan H, Shi Z.

Front Immunol. 2026 Apr 21;17:1758356. doi: 10.3389/fimmu.2026.1758356. eCollection 2026.

Neuroprotective Effects of Eugenol in Alzheimer's Disease: Mitigating Oxidative Stress, Inflammation and Amyloid Plaques

Kakkar A, Singh H, Anand A, Chopra H, Mishra AK.

Curr Pharm Des. 2026;32(7):493-504. doi: 10.2174/0113816128373290250620054118.

The Ubiquitin-proteasome system in neuroinflammation and neurodegeneration: Molecular insights and therapeutic avenues

Guo Y, Wang N, Tao Z, Huang X, Yu W, Zeng J, Liu X, Chen S, Hua F, Wang X.

Int Immunopharmacol. 2026 Jun 15;179:116599. doi: 10.1016/j.intimp.2026.116599. Epub 2026 Apr 11.

[Acteoside: neurobiological activity spectrum, potential in the treatment of age-associated neurodegenerative diseases]

Berezutsky MA, Andronova TA, Belonogova YV, Durnova NA.

Zh Nevrol Psikhiatr Im S S Korsakova. 2026;126(4):41-47. doi: 10.17116/jnevro202612604141.

Protein S-sulfhydration: Mechanisms and therapeutic implications in Alzheimer's disease and Parkinson's disease

Guo J, Shi C, Yu C, Wang Y, He M.

Free Radic Biol Med. 2026 Mar 16;246:431-441. doi: 10.1016/j.freeradbiomed.2026.01.033. Epub 2026 Jan 20.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias